Close Menu

NEW YORK - NeoGenomics announced Friday it has acquired the oncology division assets of genome sequencing company Human Longevity for $37 million.

The purchase was financed via available cash on hand.

Human Longevity's oncology division performs next-generation sequencing services for pharmaceutical customers and generated about $10 million in revenue last year. NeoGenomics said the company expects the oncology division to be slightly dilutive to 2020 adjusted earnings.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.